About Cornovus Pharmaceuticals
Cornovus Pharmaceuticals is a private company based in Farmington, Connecticut. It has reported $3,073,544 raised in three offerings on Form D since March 2014.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 22, 2024 | Jan 26, 2024 | $500,000of $2.0M target | 1 | $500K | Equity, DebtRule 506(c) | Form D ↗ |
| Aug 10, 2016 | Aug 11, 2016 | $982,600of $2.2M target | 2 | $491K | EquityRule 506(b) | Form D ↗ |
| Feb 28, 2014 | Mar 3, 2014 | $1,590,944fully sold | 1 | $1.5M | EquityRule 506(b) | Form D ↗ |
| Total, three offerings | $3,073,544 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Cornovus Pharmaceuticals's Form D filed Jan 26, 2024.
Earlier filings also listed Timothy Shannon (director, last listed Aug 2016), Raymond Neag (director, last listed Aug 2016), Glenn Mattes (chief executive officer and director, last listed Aug 2016), Daniel Wagner (director, last listed Aug 2016), Bruce Liang (director, last listed Aug 2016) and Robert Van Allen (president, last listed Mar 2014).